

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/569,583	First Named Inventor: Neil Gallagher
371 Filing Date: February 23, 2006	Attorney Docket No.: 101213-1P US
Examiner: Julie Ha	Group Art Unit : 1654
Customer No.: 44992	Confirmation No.: 5947
Title: Combination comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an LHRH analogue and/or bisphosphonate	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## DECLARATION UNDER 37 C.F.R. § 1.131

JON OWEN CURWEN declares:-

1. That he holds the degree(s) BSc (Hons) from Bradford University and MPhil awarded for work in association with the University of Bath and that he is an associate Principal Scientist in the Cancer and Infection Research Department of ASTRAZENECA UK Limited.
2. That he is an inventor on the above referenced patent application having the title of "Combination comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an LHRH analogue and/or bisphosphonate" which has been assigned U.S. Patent Application Serial No. 10/569,583 and has an international filing date of September 10, 2004.
3. That he is the author of poster number 340 entitled "ZD4054: A Specific Endothelin A Receptor Antagonist With Potential Utility in Prostate Cancer and Metastatic Bone Disease" presented at AACR, Frankfurt, Germany between 19 and 22 November 2002 ("the Curwen Reference").